Related articles

• Mycobacterium smegmatis enhances shikonin-induced immunogenic cell death—an efficient in situ tumor vaccine strategy
  2024, 38(4): 369-381. DOI: 10.7555/JBR.38.20240049
• Anticancer therapeutic strategies for targeting mutant p53-Y220C
  2024, 38(3): 222-232. DOI: 10.7555/JBR.37.20230093
• Galectin-14 promotes hepatocellular carcinoma tumor growth via enhancing heparan sulfate proteoglycan modification
  2023, 37(6): 418-430. DOI: 10.7555/JBR.37.20230085
• E26 transformation-specific 1 is implicated in the inhibition of osteogenic differentiation induced by chronic high glucose by directly regulating Runx2 expression
  2022, 36(1): 39-47. DOI: 10.7555/JBR.35.20210123
• Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms
  2021, 35(3): 179-188. DOI: 10.7555/JBR.34.20200039
• The current status of malignant hyperthermia
  2020, 34(2): 75-85. DOI: 10.7555/JBR.33.20180089
• Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer
  2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
• Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma
  2012, 26(4): 274-277. DOI: 10.7555/JBR.26.20110103
• Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis
  2011, 25(1): 25-32. DOI: 10.1016/S1674-8301(11)60003-1
• The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer
  2010, 24(1): 51-57.